Advisors Preferred LLC Sells 2,183 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Advisors Preferred LLC cut its holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 47.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,372 shares of the company’s stock after selling 2,183 shares during the period. Advisors Preferred LLC’s holdings in Centessa Pharmaceuticals were worth $42,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in CNTA. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after buying an additional 826 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Centessa Pharmaceuticals by 103.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after buying an additional 1,509 shares during the last quarter. Walleye Capital LLC bought a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter worth about $187,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Centessa Pharmaceuticals by 99.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock worth $217,000 after buying an additional 6,785 shares during the last quarter. Finally, Harbour Capital Advisors LLC bought a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter worth about $259,000. 82.01% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, insider Gregory M. Weinhoff sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $17.66, for a total value of $176,600.00. Following the completion of the sale, the insider now owns 183,266 shares of the company’s stock, valued at approximately $3,236,477.56. This represents a 5.17 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Saurabh Saha sold 87,496 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $18.46, for a total transaction of $1,615,176.16. Following the completion of the sale, the chief executive officer now directly owns 575,661 shares of the company’s stock, valued at $10,626,702.06. The trade was a 13.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 421,697 shares of company stock valued at $7,211,475 in the last three months. Company insiders own 11.59% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Guggenheim boosted their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, November 15th. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating for the company. Seven analysts have rated the stock with a buy rating, According to MarketBeat, Centessa Pharmaceuticals presently has an average rating of “Buy” and an average price target of $25.83.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock opened at $19.03 on Friday. The stock has a market cap of $2.51 billion, a price-to-earnings ratio of -12.44 and a beta of 1.53. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. Centessa Pharmaceuticals plc has a 1 year low of $7.38 and a 1 year high of $19.09. The firm has a 50-day moving average of $16.77 and a two-hundred day moving average of $15.40.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.05. On average, research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.